Promising NMOSD attack treatment trial pulled before it began
NCT ID NCT06673394
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This study aimed to test the drug eculizumab for treating sudden attacks of neuromyelitis optica spectrum disorder (NMOSD) in adults who test positive for a specific antibody. The goal was to see if the drug could quickly reduce disability by blocking harmful immune system activity. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.